Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement.

Autor: Chiong W; Department of Neurology, University of California San Francisco, San Francisco, CA, USA winston.chiong@ucsf.edu., Tolchin BD; Department of Neurology, Yale School of Medicine, New Haven, CT, USA., Bonnie RJ; School of Law, University of Virginia, Charlottesville, VA, USA., Busl K; Department of Neurology, University of Florida, Gainesville, FL, USA., Cruz-Flores S; Department of Neurology, Paul L. Foster School of Medicine Texas Tech University Health Sciences Center, El Paso, TX, USA., Epstein LG; Departments of Neurology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Greene EP; Department of Neurology, Houston Methodist Hospital, Houston, TX, USA., Illes J; Neuroethics Canada and Division of Neurology, University of British Columbia, Vancouver, BC, Canada., Kirschen M; Departments of Anesthesia & Critical Care, Pediatrics and Neurology, Children's Hospital of Pennsylvania, Philadelphia, PA, USA., Larriviere DG; Inova Neuroscience and Spine Institute, Falls Church, VA, USA., Mantri S; Department of Neurology, Duke University, Durham, NC, USA., Rubin MA; Departments of Neurology & Neurotherapeutics and Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA., Stern BJ; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA., Taylor LP; Departments of Neurology and Neurosurgery, University of Washington, Seattle, WA, USA.
Jazyk: angličtina
Zdroj: Neurology [Neurology] 2022 Jan 25; Vol. 98 (4), pp. 154-159. Date of Electronic Publication: 2022 Jan 25.
DOI: 10.1212/WNL.0000000000013053
Databáze: MEDLINE